HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALEBUND-B

27.000

-1.580-5.53%

Volume:685.70K

Turnover:18.45M

Market Cap:9.40B

PE:-8.79

High:28.800

Open:28.260

Low:25.500

Close:28.580

52wk High:46.820

52wk Low:22.480

Shares:348.00M

HK Float Shares:236.00M

Volume Ratio:2.06

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-3.071

ROE:--

ROA:-33.01%

PB:5.70

PE(LYR):-8.79

PS:65.46

Loading ...

Overview Company News Filings

AleBund-B Shares Jump Nearly 7% in Early Trading as Institution Says AP308 Could Unlock a Broader IgA Nephropathy Market

Five Straight Gains, Outperforming Hang Seng by 18.5 Points Since the Recent Low: Is the Kidney Disease Wave Finally Here?

Alebund Pharmaceuticals Reports Stable Share Capital and Maintains Public Float Compliance for September 2026

Bulletin Express

Alebund Posts 1H26 Revenue Surge on Licensing Deal; AP301 China NDA Accepted

Bulletin Express

Shares of ALEBUND-B Surge Over 17% in Afternoon Trading on US FDA Approval for IgA Nephropathy Drug Candidate

Alebund Pharmaceuticals (Jiangsu) Says IND Application for AP308 Cleared by U.S. FDA

ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308

Alebund Pharmaceuticals (Jiangsu) - AP308 Clinical Trial Planned Soon Following FDA Ind Clearance

THOMSON REUTERS

Alebund Pharma Wins US FDA Clearance to Start AP308 IgA Nephropathy Trial

Alebund Pharmaceuticals (Jiangsu) - Investigational New Drug Application for AP308 for Treatment of Iga Nephropathy Cleared by U.S. FDA

THOMSON REUTERS

HK Grey Market | EXCELLAND ROBOT Surges Over 93%, Generating Over HK$2,700 in Paper Gains Per Lot

Tiger Newspress

Hong Kong Stock Market Alert | ALEBUND-B (09637) Surges Over 6% on Stock Connect Inclusion and Index Membership, Mircera Sales Jump Approximately 105% Boosting Commercial Momentum

Alebund Pharma Added to Two Chinese Stock Connect Programs

MT Newswires Live

ALEBUND-B Announced H Shares Inclusion in Stock Connect and Hang Seng Composite Index

ALEBUND-B (09637) H Shares Set to Join Stock Connect and Hang Seng Composite Index

Unpacking ALEBUND-B's First Half Results: The Compounding Growth Logic of a Kidney Disease-Focused Biopharma

Alebund Pharmaceuticals HY26 Net Loss Narrows 22.5% to RMB 162.55 Million; Revenue Rises to RMB 104.16 Million

Alebund Pharmaceuticals (Jiangsu) Ltd - Board Did not Recommend Distribution of an Interim Dividend

THOMSON REUTERS

Alebund Pharmaceuticals (Jiangsu) Ltd - Hy Loss Attributable Rmb162.6 Mln

THOMSON REUTERS

Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/09637/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"ALEBUND-B","latestPrice":27,"timestamp":1791446895780,"preClose":28.58,"halted":0,"volume":685700,"delay":0,"changeRate":-0.05528341497550729,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"Closed","change":-1.58,"latestTime":"10-08 16:08:15","open":28.26,"high":28.8,"low":25.5,"amount":18447428,"amplitude":0.115465,"askPrice":27.02,"askSize":200,"bidPrice":27,"bidSize":1700,"shortable":0,"etf":0,"ttmEps":-2.326,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791509400000},"marketStatusCode":5,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":28.58,"openAndCloseTimeList":[[1791423000000,1791432000000],[1791435600000,1791446400000]],"volumeRatio":2.063591,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":236000000,"roa":"-33.01%","roe":"--","lyrEps":-3.071284,"volumeRatio":2.063591,"shares":348000000,"dividePrice":0,"high":28.8,"amplitude":0.115465,"preClose":28.58,"low":25.5,"week52Low":22.48,"pbRate":"5.70","psRate":"65.46","week52High":46.82,"institutionHeld":0,"latestPrice":27,"committee":0.789474,"eps":-3.071284,"divideRate":0,"volume":685700,"delay":0,"ttmEps":-2.326,"open":28.26,"prevYearClose":22.6,"prevWeekClose":25.4,"prevMonthClose":24.98,"prevQuarterClose":24.98,"fiveDayClose":24.98,"twentyDayClose":25.74,"sixtyDayClose":29.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"09637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":3,"updateTime":1787846400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-10-07","current":-11.607911,"percent":0.385714,"low":-18.066068,"twenty":-12.870195,"median":-11.354992,"eighty":-10.492422,"high":-8.42626,"avg":-11.593253,"sd":1.662298,"marketCap":9712976761},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-03","current":-11.883178,"twenty":-18.03155,"median":-11.883178,"eighty":-9.78101,"marketCap":10290725554},{"date":"2026-07-10","current":-12.164969,"twenty":-13.966639,"median":-11.847257,"eighty":-11.12129,"marketCap":10521825071},{"date":"2026-07-17","current":-10.947234,"twenty":-12.322489,"median":-11.455859,"eighty":-10.783874,"marketCap":9502268378},{"date":"2026-07-24","current":-11.320561,"twenty":-11.939536,"median":-11.377389,"eighty":-10.939493,"marketCap":9828526520},{"date":"2026-07-31","current":-10.642718,"twenty":-11.840073,"median":-11.194259,"eighty":-10.78337,"marketCap":9257574772},{"date":"2026-08-07","current":-12.743391,"twenty":-12.396338,"median":-11.399787,"eighty":-10.889159,"marketCap":11106370909},{"date":"2026-08-14","current":-13.03884,"twenty":-12.987078,"median":-11.462395,"eighty":-10.903987,"marketCap":11378252693},{"date":"2026-08-21","current":-12.870195,"twenty":-13.077865,"median":-11.725167,"eighty":-10.931752,"marketCap":11255905890},{"date":"2026-08-28","current":-12.144658,"twenty":-13.077865,"median":-11.990608,"eighty":-10.959851,"marketCap":10623780741},{"date":"2026-09-04","current":-11.919154,"twenty":-12.988947,"median":-11.883178,"eighty":-10.931752,"marketCap":9787744252},{"date":"2026-09-11","current":-9.927508,"twenty":-12.953815,"median":-11.760082,"eighty":-10.889159,"marketCap":8163250588},{"date":"2026-09-18","current":-10.492422,"twenty":-12.949729,"median":-11.507967,"eighty":-10.606061,"marketCap":8639043712},{"date":"2026-09-25","current":-10.247785,"twenty":-12.923897,"median":-11.432455,"eighty":-10.595802,"marketCap":8421538284},{"date":"2026-10-02","current":-10.493123,"twenty":-12.89284,"median":-11.377389,"eighty":-10.396495,"marketCap":8632246667},{"date":"2026-10-07","current":-11.789994,"twenty":-12.870195,"median":-11.354992,"eighty":-10.492422,"marketCap":9712976761}],"updateTime":1791470484042},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140060925","title":"AleBund-B Shares Jump Nearly 7% in Early Trading as Institution Says AP308 Could Unlock a Broader IgA Nephropathy Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1140060925","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140060925?lang=en_us&edition=fundamental","pubTime":"2026-10-07 11:16","pubTimestamp":1791342972,"startTime":"0","endTime":"0","summary":"AleBund-B (09637) rose nearly 7% in early trading. As of press time, it was up 2.78% at HK$27.4, with a turnover of HK$6.4132 million.On the news front, AleBund-B recently announced that its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1161","BK1191","VXUS","BK4588","09637","159938","09939","KCAI","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112158799","title":"Five Straight Gains, Outperforming Hang Seng by 18.5 Points Since the Recent Low: Is the Kidney Disease Wave Finally Here?","url":"https://stock-news.laohu8.com/highlight/detail?id=1112158799","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112158799?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:57","pubTimestamp":1791295043,"startTime":"0","endTime":"0","summary":"On 29 September, a conference call hosted by Huatai Securities on the IgA nephropathy treatment landscape placed the differentiated mechanism of ALEBUND-B (09637.HK) AP308 squarely in front of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169000509","title":"Alebund Pharmaceuticals Reports Stable Share Capital and Maintains Public Float Compliance for September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1169000509","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169000509?lang=en_us&edition=fundamental","pubTime":"2026-10-06 16:44","pubTimestamp":1791276295,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited released its Monthly Return for Equity Issuer, confirming that there were no changes to registered or issued share capital during September 2026. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165350533","title":"Alebund Posts 1H26 Revenue Surge on Licensing Deal; AP301 China NDA Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1165350533","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165350533?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:41","pubTimestamp":1789648881,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Alebund) released its 2026 interim results, reporting a strong top-line lift driven by a one-off licensing transaction and steady growth from its commercialised anaemia...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alebund Posts 1H26 Revenue Surge on Licensing Deal; AP301 China NDA Accepted","news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151094926","title":"Shares of ALEBUND-B Surge Over 17% in Afternoon Trading on US FDA Approval for IgA Nephropathy Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1151094926","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151094926?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:58","pubTimestamp":1789451896,"startTime":"0","endTime":"0","summary":"Shares of ALEBUND-B (09637) rallied sharply in the afternoon, climbing more than 17% at one point. At the time of writing, the stock was up 12.96% to HK$25.98, with turnover reaching HK$36.28...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","VXUS","09637","BK1515","BK4588","BK4585","BK1191","09939","LABU","KCAI","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665431379","title":"Alebund Pharmaceuticals (Jiangsu) Says IND Application for AP308 Cleared by U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665431379","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665431379?lang=en_us&edition=fundamental","pubTime":"2026-09-08 23:31","pubTimestamp":1788881494,"startTime":"0","endTime":"0","summary":"Sept 8 (Reuters) - Alebund Pharmaceuticals (Jiangsu) Ltd <9637.HK>::*INVESTIGATIONAL NEW DRUG APPLICATION FOR AP308 FOR TREATMENT OF IGA NEPHROPATHY CLEARED BY U.S. FDA*Further company coverage: 9637.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nRSDYgyKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141807270","title":"ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308","url":"https://stock-news.laohu8.com/highlight/detail?id=1141807270","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141807270?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869176,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","IBBQ","MDTX","BMED","09637","09939","BK1515","BK1161","BK1191","BK1574","159151","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665416320","title":"Alebund Pharmaceuticals (Jiangsu) - AP308 Clinical Trial Planned Soon Following FDA Ind Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2665416320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665416320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:05","pubTimestamp":1788869101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA2NDWZM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132055","title":"Alebund Pharma Wins US FDA Clearance to Start AP308 IgA Nephropathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132055?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868895,"startTime":"0","endTime":"0","summary":"Alebund Pharma wins US FDA clearance to start AP308 IgA nephropathy trialAlebund Pharmaceuticals (Jiangsu) secured FDA clearance for an IND for AP308 in IgA nephropathy.Approval enables the start of a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL3brvHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320340","title":"Alebund Pharmaceuticals (Jiangsu) - Investigational New Drug Application for AP308 for Treatment of Iga Nephropathy Cleared by U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868836,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN4500RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109204741","title":"HK Grey Market | EXCELLAND ROBOT Surges Over 93%, Generating Over HK$2,700 in Paper Gains Per Lot","url":"https://stock-news.laohu8.com/highlight/detail?id=1109204741","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109204741?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:28","pubTimestamp":1788856095,"startTime":"0","endTime":"0","summary":"On Tuesday,  $EXCELLAND ROBOT(03231)$ surged over 93% in Hong Kong grey market trading. According to the prospectus, the company's revenue comes from sales of robot products and modules, AI vision...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01191","09637","03231","02672"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1183000307","title":"Hong Kong Stock Market Alert | ALEBUND-B (09637) Surges Over 6% on Stock Connect Inclusion and Index Membership, Mircera Sales Jump Approximately 105% Boosting Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1183000307","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183000307?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:22","pubTimestamp":1788834140,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) shares climbed more than 6% in Monday's session, trading up 6.02% at HK$28.52 as of the time of writing. The stock recorded a turnover of HK$6.452 million with a volume ratio of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","HSCI","BK1161","KCAI","09939","159938","VXUS","BK1515","BK4588","BK1191","BK1574","FLHK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392411","title":"Alebund Pharma Added to Two Chinese Stock Connect Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392411","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665392411?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:15","pubTimestamp":1788765338,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals'  Hong Kong-listed shares have been included in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs effective Monday.The company believes its inclusion in the cross-border trading links will help broaden its investor base and boost the trading liquidity of its shares, according to a Monday bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["82823","YANG","XPP","82843","ASHR","KWEB","CHAU","82822","FLCH","YXI","02823","BK1191","09637","CWEB","FXP","KCAI","02843","ASHS","02822","KBA","YINN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187807186","title":"ALEBUND-B Announced H Shares Inclusion in Stock Connect and Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1187807186","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187807186?lang=en_us&edition=fundamental","pubTime":"2026-09-07 09:00","pubTimestamp":1788742832,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that, in accordance with the relevant arrangements and adjustments for Stock Connect, its H shares have been included in the list of eligible securities for Stock...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09637","09939","BK1191","FLHK","BK1515","159938","BK1161","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144923293","title":"ALEBUND-B (09637) H Shares Set to Join Stock Connect and Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1144923293","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144923293?lang=en_us&edition=fundamental","pubTime":"2026-09-04 21:36","pubTimestamp":1788528973,"startTime":"0","endTime":"0","summary":"The Board of ALEBUND-B (09637) has announced that its H shares have been included in the list of eligible securities under the Stock Connect programme. This inclusion will take effect from Monday,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","FLHK","09637","159938","09939","BK1574","HSCI","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135812657","title":"Unpacking ALEBUND-B's First Half Results: The Compounding Growth Logic of a Kidney Disease-Focused Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1135812657","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135812657?lang=en_us&edition=fundamental","pubTime":"2026-08-27 08:04","pubTimestamp":1787789077,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) delivered its inaugural interim results on August 26, marking a significant milestone since its listing, with revenue scaling to 8.6 times the figure reported in the same period...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","BK1191","BK1161","09637","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797855","title":"Alebund Pharmaceuticals HY26 Net Loss Narrows 22.5% to RMB 162.55 Million; Revenue Rises to RMB 104.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797855","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797855?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:04","pubTimestamp":1787738650,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals HY26 net loss narrows 22.5% to RMB 162.55 million; revenue rises to RMB 104.16 millionAlebund posted revenue of RMB 104.16 million, up 761.2%, driven by RMB 79.3 million AP306 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL7Q1XP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792769","title":"Alebund Pharmaceuticals (Jiangsu) Ltd - Board Did not Recommend Distribution of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792769?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:01","pubTimestamp":1787738462,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792744","title":"Alebund Pharmaceuticals (Jiangsu) Ltd - Hy Loss Attributable Rmb162.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792744?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:01","pubTimestamp":1787738462,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0HX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143863458","title":"Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1143863458","media":"Stock News","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143863458?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:00","pubTimestamp":1787641221,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) climbed more than 6% in early trading, last up 3.82% at HK$33.7, with turnover reaching HK$12.45 million.On the news front, Hang Seng Indexes Company recently announced the results...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK4588","BK1161","BK4585","09939","VXUS","09637","BK1191","BK1574","159938","KCAI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}]}}